OKUR – onkure therapeutics, inc. - class a (US:NASDAQ)

News

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.
OnKure Announces New Date for Upcoming Investor Call [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com